Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

NEUROENDOCRINE CANCER

Neuroendocrine neoplasia goes molecular — time for a change

Nature Reviews Clinical Oncology volume 16, pages 149–150 (2019)Cite this article

Subjects

In a cohort of 100 patients with neuroendocrine cancer, the use of NETest enabled earlier prediction of tumour progression and resulted in a reduction in the frequency of follow-up procedures. These outcomes are exciting and promising, but limited in value by the heterogeneity of the study cohort and by suboptimal assay sensitivity and specificity.

Refers to Liu, E. et al. Assessment of NETest clinical utility in a U.S. registry-based study. Oncologist https://doi.org/10.1634/theoncologist.2017-0623 (2018).

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jensen, R. T. et al. Unmet needs in functional and nonfunctional pancreatic neuroendocrine neoplasms (PanNENs). Neuroendocrinology https://doi.org/10.1159/000494258 (2018).

    Article  PubMed  Google Scholar 

  2. Modlin, I. M. et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr. Relat.Cancer 21, 615–628 (2014).

    Article  CAS  Google Scholar 

  3. Liu, E. et al. Assessment of NETest clinical utility in a U. S. registry-based study. Oncologist https://doi.org/10.1634/theoncologist.2017-0623 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Travis, W. D. et al. (eds) Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart 4th edn Vol. 7 (IARC Press, 2015).

  5. Bosman, F. et al. (eds) Pathology and Genetics of Tumours of the Digestive System 4th edn Vol. 3 (IARC Press, 2010).

  6. Edge, S. B. et al. (eds) AJCC Cancer Staging Manual 7th edn (Springer, 2010).

  7. Razzore, P. & Arnaldi, G. Circulating neuroendocrine tumors biomarkers. Why? When? How? Suggestions for clinical practice from guidelines and consensus. J. Cancer Metastasis Treat. 2, 348–356 (2016).

    Article  CAS  Google Scholar 

  8. Kidd, M., Modlin, I. M. & Drozdov, I. Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors. BMC Genomics 15, 595 (2014).

    Article  Google Scholar 

  9. Khan, M. S. et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J. Clin. Oncol. 31, 365–372 (2013).

    Article  CAS  Google Scholar 

  10. Uri, I. & Grozinsky-Glasberg, S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin. Diabetes Endocrinol. 4, 16 (2018).

    Article  Google Scholar 

Download references

Acknowledgements

The work of G.R. is supported in part by internal university grants (Università Cattolica line D.1/2016-R412500403 and D.1 2017-R412500591).

Author information

Authors and Affiliations

  1. Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy

    Guido Rindi

  2. Charité, Campus Virchow Klinikum and Charité Mitte, University Medicine Berlin, Berlin, Germany

    Bertram Wiedenmann

Authors
  1. Guido Rindi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bertram Wiedenmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guido Rindi.

Ethics declarations

Competing interests

G.R. has received honoraria from Ipsen and Novartis for his role in their speaker’s bureau. B.W. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rindi, G., Wiedenmann, B. Neuroendocrine neoplasia goes molecular — time for a change. Nat Rev Clin Oncol 16, 149–150 (2019). https://doi.org/10.1038/s41571-018-0118-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-018-0118-8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing